Administration other than IV or IM (eg, intra-articular intrathecal). Limited clinical experience or treatment >3 days. Discontinue use if there is any organ system functions deterioration during treatment. Increased risk of CV & thrombotic adverse events associated w/ COX-2 inhibitors when taken long-term appears to be similar in those w/ or w/o known CV disease or CV risk factors. Patients w/ significant risk factors for CV events (eg, HTN, hyperlipidemia, DM, smoking). Not studied in CV revascularization procedures other than CABG. Patients w/ active or history of GI disease eg, ulceration, bleeding, or inflammatory conditions; or concomitantly using aspirin. Potential association w/ increased GI complications when co-administered w/ corticosteroids, SSRIs, other antiplatelet drugs, other NSAIDs or patients ingesting alcohol. Monitor for any serious skin reaction or severe hypotension during treatment. Discontinue use at the 1st appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Increase risk of bleeding w/ oral anticoagulants (eg, apixaban, dabigatran & rivaroxaban). Monitor anticoagulant activity in patients on warfarin (or similar agent) therapy, particularly during the 1st few days after initiation of treatment. HTN; compromised cardiac function, preexisting edema or other conditions predisposing to, or worsened by fluid retention including those taking diuretic therapy or at risk of hypovolemia. Impaired renal function, advanced renal disease. Moderate hepatic impairment (Child-Pugh class B). Carefully monitor patients for evidence of the development of severe hepatic reaction while on therapy. Initiate treatment to dehydrated patients. Avoid concomitant use w/ other nonspecific NSAIDs. Not a replacement for aspirin in the prophylactic treatment of CV disease. May affect the ability to drive or operate machinery. Do not use during pregnancy (1st & 2nd trimesters). Not recommended in childn <18 yr. Elderly.